BCS Financial Corporation

Protect against the growing gene therapy risk with new stop loss solutions.

BCS offers a comprehensive suite of self-funding solutions. From large group gene therapy to small group captives, BCS has a solution to fit your needs.

It feels like there's a growing disconnect between established players in the stop loss industry and the new entrants who crop up annually. Long-term industry experts point to warning signs that the market may be hardening. Yet every year, new players enter the market, attracted by the undeniable year-over-year growth. So what are they seeing on both sides of this equation that creates this disconnect between the insurance markets and the capital markets? And where are we all going to end up? In this episode, we bring in three pros to sort it all out: Theresa Galizia from Berkley Accident and Health, Tara Krauss from QBE North America, and Alexis Neu from Guy Carpenter. Additionally, they'll discuss why it's so rare to see an all-female panel in our industry, and what can be done about that. And then, why one panelist predicts the stop loss industry will eclipse $50 billion next year!

Gene therapies offer the promise of potential cures – at unprecedented costs. Our newest whitepaper provides an overview of the financial challenges faced by health payers and self-insureds. It offers insights into new insurance offerings that can ensure access to therapies while driving down costs and protecting payers from significantly adverse situations.

Supplemental health insurance can play an important role in helping to offset out-of-pocket costs that major medical does not fully cover, like #deductibles, #copays and more. Download our cases study today to explore real-life examples of how individuals and families have used EssentialCare supplemental health solutions to bridge the financial gap during medical emergencies.

Stop Loss GTS sits alongside traditional stop loss, and provides “carve out” protection for gene therapy ingredient costs.